The latest label expansion for Novartis’s Fabhalta (iptacopan), for C3 glomerulopathy (C3G), allows the firm to expand its growing presence in the renal disease space, which the Swiss drug maker will do by employing digital technology and artificial intelligence to reach patients with the rare kidney disease.
The US Food and Drug Administration approved Fabhalta, a complement factor B inhibitor, on 20 March for reducing proteinuria in...
Welcome to Scrip
Create an account to read this article
Already a subscriber?